Parkinson's disease
Replacement of dopaminergic neurons and reduction of neuroinflammation to slow the progression of motor and non-motor symptoms.
Request informationTreatments / 02
Eight directions at Han's United — from neurodegenerative diseases to endocrine disorders. The protocol is chosen by the academic board individually for each diagnosis.
Featured / 03
Indications for which we have prepared in-depth materials — mechanism of action, protocol, expected results, FAQ. Other directions are in the catalogue below.
Neurology
A group of permanent disorders of movement and posture caused by damage to the developing brain. Cell therapy targets neuroprotection, remyelination and reduction of chronic neuroinflammation.
Read moreNeurology
A neurodevelopmental disorder with persistent communication impairments and behavioural stereotypies. Cell therapy reduces neuroinflammation, improves the quality of interneuronal connections, and supports social and cognitive development.
Read moreNeurology
Acute cerebrovascular accident with neuronal death in the infarct zone and the formation of a neurological deficit. Cell therapy targets angiogenesis, penumbra neuroprotection, and support of neuroplasticity.
Read moreAutoimmune
A chronic systemic autoimmune disease with damage to the skin, joints, kidneys, lungs, and central nervous system. Cell therapy modulates the autoimmune response, reduces the need for steroids and cytostatics, and slows damage to target organs.
Read moreCardiovascular
Acute ischaemia and necrosis of a heart muscle area due to coronary artery occlusion. Cell therapy in the subacute and chronic periods targets myocardial regeneration, angiogenesis, and improvement of ejection fraction.
Read moreEndocrinology
A chronic metabolic disease with insulin resistance and relative insulin deficiency. Cell therapy reduces systemic inflammation, improves tissue insulin sensitivity, and supports residual pancreatic β-cell function.
Read moreGynecology
Decline or cessation of ovarian function in women under 40 with oestrogen deficiency and fertility impairment. Cell therapy targets ovarian tissue regeneration, restoration of the follicular pool, and normalisation of the hormonal profile.
Read moreOrthopedics
A chronic degenerative joint disease with cartilage destruction, subchondral bone remodelling, and osteophyte formation. Cell therapy targets cartilage regeneration, reduction of inflammation, and pain relief.
Read moreGastroenterology
A chronic progressive liver disease with replacement of parenchyma by connective tissue and disruption of organ architecture. Cell therapy targets reduction of fibrogenesis, hepatocyte regeneration, and improvement of liver function parameters.
Read moreHematology
Graft-versus-host disease — an immune complication after allogeneic bone marrow or haematopoietic stem cell transplantation. Mesenchymal cell therapy reduces the risk of acute and chronic GVHD through potent immunomodulation.
Read moreCatalogue / 04
All indications are grouped into eight clinical directions. Detailed pages are marked with the DETAIL badge — others are available on individual request.
11 indications
Cerebral palsy, autism, stroke, Parkinson's, ALS, spinal cord injuries, Alzheimer's, TBI, epilepsy, MS, dementia — living-cell neuroregenerative therapy.
A group of permanent disorders of movement and posture caused by damage to the developing brain. Cell therapy targets neuroprotection, remyelination and reduction of chronic neuroinflammation.
Open pageA neurodevelopmental disorder with persistent communication impairments and behavioural stereotypies. Cell therapy reduces neuroinflammation, improves the quality of interneuronal connections, and supports social and cognitive development.
Open pageAcute cerebrovascular accident with neuronal death in the infarct zone and the formation of a neurological deficit. Cell therapy targets angiogenesis, penumbra neuroprotection, and support of neuroplasticity.
Open pageReplacement of dopaminergic neurons and reduction of neuroinflammation to slow the progression of motor and non-motor symptoms.
Request informationMotor neuron neuroprotection and reduction of neuroinflammation — supportive therapy for ALS.
Request informationRegeneration of nerve tissue at the injury site, restoration of conduction and motor function.
Request informationReduction of neuroinflammation, support of cognitive function, and slowing of degenerative processes.
Request informationNerve tissue recovery after TBI, rehabilitation of motor and cognitive function.
Request informationStabilisation of brain electrical activity through immunomodulation and reduction of neuroinflammation.
Request informationImmunomodulation, halting demyelination and supporting remyelination of nerve fibres.
Request informationCognitive support in vascular and mixed dementia — improvement of cerebral microcirculation.
Request information4 indications
SLE, rheumatoid arthritis, psoriasis, scleroderma — immunomodulation with mesenchymal cells.
A chronic systemic autoimmune disease with damage to the skin, joints, kidneys, lungs, and central nervous system. Cell therapy modulates the autoimmune response, reduces the need for steroids and cytostatics, and slows damage to target organs.
Open pageImmunomodulation, reduction of joint inflammation, and slowing of erosive changes.
Request informationSkin regeneration through normalisation of immune response and reduction of systemic inflammation.
Request informationSlowing of skin and internal organ fibrosis through mesenchymal cell immunomodulation.
Request information5 indications
MI, heart failure, ischemic cardiomyopathy, dilated cardiomyopathy, atherosclerosis — myocardial regeneration.
Acute ischaemia and necrosis of a heart muscle area due to coronary artery occlusion. Cell therapy in the subacute and chronic periods targets myocardial regeneration, angiogenesis, and improvement of ejection fraction.
Open pageMyocardial regeneration, improved ejection fraction and reduction of chronic heart failure symptoms.
Request informationHeart muscle recovery in ischaemic heart disease via angiogenesis and myocardial regeneration.
Request informationSlowing of heart failure progression and improvement of myocardial contractile function.
Request informationVascular endothelium recovery, reduction of systemic inflammation and stabilisation of atherosclerotic plaques.
Request information4 indications
Type 1 and type 2 diabetes, diabetic complications, hormonal disorders.
A chronic metabolic disease with insulin resistance and relative insulin deficiency. Cell therapy reduces systemic inflammation, improves tissue insulin sensitivity, and supports residual pancreatic β-cell function.
Open pageImmunomodulation of the autoimmune process and support of residual β-cell function in the pancreas.
Request informationTissue regeneration in diabetic nephropathy, neuropathy and trophic changes.
Request informationEndocrine function recovery through glandular tissue regeneration and immunomodulation.
Request information3 indications
Premature ovarian failure, uterine adhesions, reproductive health.
Decline or cessation of ovarian function in women under 40 with oestrogen deficiency and fertility impairment. Cell therapy targets ovarian tissue regeneration, restoration of the follicular pool, and normalisation of the hormonal profile.
Open pageEndometrial regeneration after adhesions and restoration of reproductive function.
Request informationFertility support, restoration of endocrine function and oocyte quality.
Request information5 indications
Osteoarthritis, avascular necrosis, osteoporosis, delayed fracture healing, tendon and ligament injuries.
A chronic degenerative joint disease with cartilage destruction, subchondral bone remodelling, and osteophyte formation. Cell therapy targets cartilage regeneration, reduction of inflammation, and pain relief.
Open pageBone tissue regeneration in avascular necrosis of the femoral head and other joints.
Request informationRestoration of bone density through stimulation of osteogenesis and bone remodelling balance.
Request informationOsteogenesis stimulation in fracture non-union and delayed healing.
Request informationTendon and ligament regeneration after sports and everyday injuries via local cell administration.
Request information5 indications
Liver fibrosis and cirrhosis, liver failure, Crohn's disease, ulcerative colitis.
A chronic progressive liver disease with replacement of parenchyma by connective tissue and disruption of organ architecture. Cell therapy targets reduction of fibrogenesis, hepatocyte regeneration, and improvement of liver function parameters.
Open pageSlowing of fibrotic processes and hepatocyte regeneration in early stages of liver fibrosis.
Request informationLiver function support and hepatocyte regeneration in acute and chronic liver failure.
Request informationImmunomodulation and reduction of intestinal inflammation, mucosal healing in Crohn's disease.
Request informationRestoration of colonic mucosa and immunomodulation in ulcerative colitis.
Request information2 indications
Hematopoietic recovery, prevention of graft-versus-host disease (GVHD).
Graft-versus-host disease — an immune complication after allogeneic bone marrow or haematopoietic stem cell transplantation. Mesenchymal cell therapy reduces the risk of acute and chronic GVHD through potent immunomodulation.
Open pageHaematopoietic support after chemotherapy and radiotherapy — accelerated bone marrow recovery.
Request informationContact a medical coordinator — the academic board will review your history and assess whether cell therapy is suitable in your case.
We use cookies and analytics services to improve the website experience. Privacy Policy